Insulet Q4 2022 Earnings Report
Key Takeaways
Insulet Corporation reported a strong fourth quarter in 2022, with revenue reaching $369.7 million, a 20.1% increase compared to the previous year. The growth was primarily fueled by a 32.8% increase in total Omnipod revenue, with significant contributions from the U.S. market. The company's strategic priorities and the commercial launch of Omnipod 5 contributed to the positive results.
Q4 2022 revenue increased by 20.1% year-over-year to $369.7 million.
Total Omnipod revenue increased by 32.8% year-over-year.
U.S. Omnipod revenue increased by 45.0% year-over-year.
Adjusted EBITDA was $71.4 million, representing 19.3% of revenue.
Insulet
Insulet
Insulet Revenue by Segment
Forward Guidance
The Company expects revenue growth of 11% to 14% for the quarter ending March 31, 2023. For the year ending December 31, 2023, the Company expects gross margin of 65% to 66% and operating margin of high-single digits.
Positive Outlook
- Total Omnipod revenue growth of 22% to 25% for the quarter ending March 31, 2023.
- U.S. Omnipod revenue growth of 33% to 36% for the quarter ending March 31, 2023.
- Total Omnipod revenue growth of 17% to 22% for the year ending December 31, 2023.
- U.S. Omnipod revenue growth of 21% to 26% for the year ending December 31, 2023.
- Gross margin of 65% to 66% for the year ending December 31, 2023.
Challenges Ahead
- Drug Delivery revenue decline of (100)% to (95)% for the quarter ending March 31, 2023.
- International Omnipod revenue growth of 4% to 7% for the quarter ending March 31, 2023.
- Drug Delivery revenue decline of (55)% to (45)% for the year ending December 31, 2023.
- International Omnipod revenue growth of 6% to 10% for the year ending December 31, 2023.
- Operating margin of high-single digits for the year ending December 31, 2023.
Revenue & Expenses
Visualization of income flow from segment revenue to net income